Tag: ophthalmic pharmaceuticals
Pharma and medical device company, Paragon BioTeck receives EN ISO 13485:2012 Certification
NEWS: (PORTLAND, Ore.) Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today that it has received EN ISO 13485:2012 certification, signifying the company's successful implementation of an effective quality management system.
American Academy of Ophthalmology Annual Meeting 2014 to include exhibit from Paragon BioTeck, Inc.
PORTLAND, Ore. /eNewsChannels/ -- NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago on October 18-21, 2014.
Paragon BioTeck, Inc. receives FDA Approval for Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent
PORTLAND, Ore. /eNewsChannels/ -- NEWS: Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.
